KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TherapeuticsMD (TXMD) Common Equity (2016 - 2025)

TherapeuticsMD's Common Equity history spans 16 years, with the latest figure at $26.9 million for Q4 2025.

  • For Q4 2025, Common Equity fell 1.8% year-over-year to $26.9 million; the TTM value through Dec 2025 reached $26.9 million, down 1.8%, while the annual FY2025 figure was $26.9 million, 1.8% down from the prior year.
  • Common Equity reached $26.9 million in Q4 2025 per TXMD's latest filing, down from $27.4 million in the prior quarter.
  • In the past five years, Common Equity ranged from a high of $35.1 million in Q4 2022 to a low of -$140.6 million in Q1 2022.
  • Average Common Equity over 5 years is -$2.5 million, with a median of $27.2 million recorded in 2024.
  • Peak YoY movement for Common Equity: tumbled 1383.22% in 2022, then skyrocketed 219.68% in 2023.
  • A 5-year view of Common Equity shows it stood at -$93.6 million in 2021, then surged by 137.54% to $35.1 million in 2022, then fell by 16.66% to $29.3 million in 2023, then fell by 6.55% to $27.4 million in 2024, then dropped by 1.8% to $26.9 million in 2025.
  • Per Business Quant, the three most recent readings for TXMD's Common Equity are $26.9 million (Q4 2025), $27.4 million (Q3 2025), and $27.3 million (Q2 2025).